TRAVERE THERAPEUTICS, INC. Amortization of Debt Discount (Premium)
TRAVERE THERAPEUTICS, INC. (TVTX) reported Amortization of Debt Discount (Premium) of $382.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2019-02-26
- TRAVERE THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2015-06-30 was $475.31K.
- TRAVERE THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2015-03-31 was $469.69K.
- TRAVERE THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2014-12-31 was -$534.00K.
- TRAVERE THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2014-09-30 was $478.00K.
- TRAVERE THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2018 was $382.00K, a 71.45% decline from fiscal 2017.
- TRAVERE THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2017 was $1.34M, a 21.97% increase from fiscal 2016.
- TRAVERE THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2016 was $1.10M, a 175.63% increase from fiscal 2015.
- TRAVERE THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2015 was $398.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $382.00K 10-K · filed 2019-02-26 | ||||
| 2017-12-31 | $1.34M 10-K · filed 2019-02-26 | ||||
| 2016-12-31 | $1.10M 10-K · filed 2019-02-26 | ||||
| 2015-12-31 | $398.00K 10-K · filed 2018-07-06 | ||||
| 2015-06-30 | $475.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $945.00K 10-Q · filed 2015-08-10 | $411.00K derived: sum of 3 quarters · filed 2017-03-01 | $889.00K derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $469.69K 10-Q · filed 2015-05-11 | -$64.31K derived: sum of 2 quarters · filed 2017-03-01 | $413.69K derived: sum of 3 quarters · filed 2017-03-01 | ||
| 2014-12-31 | -$534.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$56.00K derived: sum of 2 quarters · filed 2017-03-01 | $0.00 10-K · filed 2017-03-01 | $1.01M 10-K · filed 2015-03-11 | |
| 2014-09-30 | $478.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $534.00K 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $56.00K 10-Q · filed 2015-08-10 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 | ||||
| 2012-02-29 | $0.00 10-K · filed 2012-05-24 | ||||
| 2011-11-30 | $500.00 10-Q · filed 2012-01-11 | $0.00 10-Q · filed 2012-01-11 | |||
| 2011-02-28 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-05-24 | $2.58K derived: sum of 2 quarters · filed 2012-05-24 | $8.33K 10-K · filed 2012-05-24 | ||
| 2010-11-30 | $2.58K 10-Q · filed 2012-01-11 | $8.33K 10-Q · filed 2012-01-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |